The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | Advances in the clinical understanding of advanced SM and educational gaps that remain
Deepti Radia, MBBS, BSc, MRCPI, FRCPath, MSc Med Ed, Guy’s and St Thomas’ NHS Foundation Trust, London, UK, briefly discusses advances in the clinical understanding of advanced systemic mastocytosis (SM), highlighting the impact of improved knowledge on the molecular landscape of the disease on risk stratification and prognostication. She also notes that while significant progress has been made, much remains to be learned about the associated hematologic neoplasm (AHN) component of advanced SM, which is present in the majority of patients. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
